Divestment
Syntaxin
Syntaxin developed engineered botulinum toxin biologics for pain, bladder disorders, and endocrine diseases.
Key Facts
- Sector
Life Sciences
- Country
United Kingdom
- Fund
LSP 3
- Entry
2007
- Exit
2013
Responsible Partner
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.